Flavopiridol (Alvocidib) 化学構造
分子量: 401.84

高品質保証

カスタマーフィードバック(1)

Quality Control & MSDS

製品説明

  • Compare CDK Inhibitors
    CDK製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 Flavopiridol (Alvocidib)は、CDK1、CDK2、CDK4、CDK5、CDK6とCDK9を目標としている汎cdk阻害剤で、IC50 がそれぞれ 30 nM、 170 nM、 100 nM、 170 nM、 80 nM と 20 nMです。
ターゲット

CDK1/Cyclin B1

CDK2/Cyclin E

CDK4/Cyclin D1

CDK5/p25

CDK6/Cyclin

CDK9/Cyclin T

IC50

30 nM

170 nM

100 nM [1]

170 nM

80 nM [2]

20 nM [3]

In vitro試験 Flavopiridol displays less activity against unrelated kinases such as MAP, PAK, PKC, and EGFR with IC50 of >14 μM. Flavopiridol significantly inhibits the colony growth of HCT116, A2780, PC3, and Mia PaCa-2 cells with IC50 of 13 nM, 15 nM, 10 nM and 36 nM, respecitively. [1] Flavopiridol also potently inhibits the activity of Glycogen synthase kinase-3 (GSK-3) with an IC50 of 280 nm. [2] Compared with other CDKs, Flavopiridol inhibits the activity of CDK7 less potently with IC50 of 875 nM. Flavopiridol (0.5 μM) inhibits both pSer807/811 Rb and pThr199 NPM, whereas mild changes are observed at pThr821 Rb. Flavopiridol also decreases the overall RNA polymerase II level, as well as the phosphorylation of RNA polymerase II on the CTD repeats at Ser2 Ser5. [3] As a broad spectrum CDK inhibitor, Flavopiridol can inhibit cell cycle progression in either G1 or G2. Flavopiridol (0.3 μM) induces G1 arrest in either MCF-7 or MDA-MB-468 cells by inhibition of the CDK4 or CDK2 kinase activity. [4] Flavopiridol exhibits potent cytotoxicity against a wide variety of tumor cell lines with IC50 values ranging form 16 nM for LNCAP to 130 nM for K562. [5]
In vivo試験 Administration of Flavopiridol at 7.5 mg/kg for 7 days displays slight antitumor activity against P388 murine leukemia, resulting in %T/C value of 110, and active against the human A2780 ovarian carcinoma implanted sc in nude mice, producing 1.5 log cell kill (LCK). [5] Flavopiridol treatment at 1-2.5 mg/kg for 10 days significantly suppresses collagen-induced arthritis in mice in a dose-dependent manner, by inhibiting synovial hyperplasia and joint destruction, whereas serum concentrations of anti-collagen type II (CII) Abs and proliferative responses to CII are maintained. [6] In the p21-intact Hct116 xenografts in nude mice, administration of CPT-11 (100 mg/kg) followed by Flavopiridol (3 mg/kg) 7 and 16 hours later significantly inhibits tumor regression by 86% and 82%, respectively, displaying >2 fold inhibition compared with CPT-11 alone by 40 %. The combination produces ~30% complete response rate (CR) in contrast to CPT-11 alone where no CR is found. [7]
臨床試験 A Phase I/II study of Flavopiridol to treat relapsed mantle cell lymphoma or diffuse large B-cell lymphoma has been completed.
特集 First CDK inhibitor to be used in human clinical trials.

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

CDK kinase assay For CDK1/cyclin B1 kinase assay, kinase reactions consist of 100 ng of baculovirus expressed GST-CDK1/cyclin B1 (human) complex, 1 μg histone HI, 0.2 μCi [γ-33P]ATP, 25 μM ATP in 50 μL kinase buffer (50 mM Tris, pH 8.0, 10 mM MgCl2, 1 mM EGTA, 0.5 mM DTT). For CDK2/cyclin E kinase assay, kinase reactions consist of 5 ng of baculovirus expressed GST-CDK2/cyclin E (human) complex, 0.5 μg GST-RB fusion protein (amino acids 776-928 of retinoblastoma protein), 0.2 μCi [γ-33P]ATP, 25 μM ATP in 50 μL kinase buffer (50 mM Hepes, pH 8.0, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT). For CDK4/cyclin D1 kinase assay, kinase reactions consist of 150 ng of baculovirus expressed GST-CDK4/cyclin D1 (human), 280 ng of Stag-cyclin D1, 0.5 μg GST-RB fusion protein (amino acids 776-928 of retinoblastoma protein), 0.2 μCi [γ-33P]ATP, 25 μM ATP in 50 μL kinase buffer (50 mM Hepes, pH 8.0, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT). Reactions are incubated for 45 minutes for CDK1 and CDK2, or 1 hour for CDK4 at 30 °C and stopped by the addition of cold trichloroacetic acid (TCA) to a final concentration 15%. TCA precipitates are collected onto GF/C unifilter plates using a Filtermate universal harvester and the filters are quantitated using a TopCount 96-well liquid scintillation counter. Flavopiridol is dissolved at 10 mM in dimethylformamide (DMF) and evaluated at six concentrations, each in triplicate. The final concentration of DMF in the assay = 2%. IC50 values are derived by nonlinear regression analysis and have a coefficient of variance = 16%. To assay Flavopiridol activity on CDK6, a filter-binding assay is established. The following are combined in the reaction mixture: 2 μL of CDK6 (0.7 mg/μL), 5 μL of histone H1 (6 mg/mL), 14 μL of kinase buffer (60 mM β-glycerophosphate, 30 mM p-nitrophenyl phosphate, 25 mM MOPS (pH 7.0), 5 mM EGTA, 15 mM MgCl2, 1 mM DTT, 0.1 mM Na-vanadate), 3 μL of increasing concentrations of Flavopiridol diluted in 50% DMSO, and 6 μL of 33P-ATP (1 mCi/mL) in nonradioactive ATP at 90 μM concentration (final concentration: 15 μM). The assay is initiated by the addition of 33P-ATP. The reaction is incubated for 20 minutes at 30°C. A 25 μL aliquot of the supernatant is then spotted onto Whatman P81 phosphocellulose paper. Filters are washed 5 times with 1% phosphoric acid solution. Wet filters are counted in the presence of 1 mL of scintillation fluid. Cdk9 activity is measured using 50 nM of recombinant Cdk9/cyclin T in 50 mM HEPES pH 7.5, 10 mM MgCl2, 1 mM DTT, 3 μM Na3VO4, 150 μM RNA polymerase CDT peptide and 80 μM ATP. Cdk7 assay is performed in the same buffer using 37 nM of purified kinase in the presence of 200 μM ATP and 10 μM myelin binding protein as a substrate. The potency of Flavopiridol toward CDK9 and CDK7 is determined using either a strong anion exchanger (Dowex 1-X8 resin, formate form)-based assay or a scintillation proximity assay. IC50 values are calculated from the dose-response curves.

細胞アッセイ:

[5]

細胞株 MCF-7, LNCAP, PC3, HCT116, CACO-2, A549, HL60, K562 cells and et al.
濃度 Dissolved in DMSO, final concentrations ~10 μM
反応時間 72 hours
実験の流れ

Cells are exposed to various concentrations of Flavopiridol for 72 hours at which time the tetrazolium dye, MTS in combination with phenazine methosulfate, is added. After 3 hours, the absorbency is measured at 492 nm, which is proportional to the number of viable cells. The results are expressed as IC50 values. For cell Cycle analysis, cells are fixed in paraformaldehyde and ethanol, washed, resuspended in staining solution of TdT enzyme and FITC-dUTP, washed, stained with PI following RNase treatment, and then analyzed by flow cytometry.

動物実験:

[5]

動物モデル Female Balb/c×DBA/2J F1 mice inoculated ip with P388 ascites leukemic cells, and Balb/c nu/nu nude mice subcutaneous implanted with A2780, Br-cycE, or A431 cells
製剤 Dissolved in a mixture of Cremophor/ethanol (50:50), and diluted in water
投薬量 ~7.5 mg/kg/day
投与方法 Injection i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

分子量 401.84
化学式

C21H20ClNO5

CAS No. 146426-40-6
保管 2年-20℃
6月-80℃in solvent
別名 NSC 649890 HCl,HMR-1275
溶解度 (25°C) * In vitro DMSO 15 mg/mL (37.32 mM)
エタノール 8 mg/mL (19.9 mM)
<1 mg/mL (<1 mM)
In vivo
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 2-(2-chlorophenyl)-5,7-dihydroxy-8-((3S,4R)-3-hydroxy-1-methylpiperidin-4-yl)-4H-chromen-4-one

カスタマーフィードバック (1)


Click to enlarge
Rating
Source PNAS, 2011, 108, 8417. Flavopiridol (Alvocidib) purchased from Selleck
Method Fluorescent Microscopy and Confocal Imaging
Cell Lines Tg:Pomc-Pttg embryo, Pomc-eGFP embryo
Concentrations 50 μM
Incubation Time 18-48 h
Results Although flavopiridol retarded early embryonic development before corticotroph ontogeny occurred, in vivo treatment of zebrafish embryos with R-roscovitine, olomoucine, PD-0332991, and CAY10572 starting at 18 hpf caused no apparent growth defect by 40 hpf. Strikingly, R-roscovitine-treated embryos exhibited approximately 40% reduction in pituitary POMC-eGFP expression compared with controls.

文献中の引用 (12)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related CDK 阻害剤

  • SU9516

    SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.

  • Ro-3306

    RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

  • Purvalanol A

    Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.

  • AT7519 HCl

    AT7519 HCl is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM in cell-free assays. It is less potent to CDK3 and little active to CDK7. Phase 2.

  • Palbociclib (PD-0332991) HCl

    Palbociclib (PD-0332991) HClはCdksを抑制、Cdk4/ cyclin D1とCdk6/ cyclin D2に作用する時、IC50がそれぞれ11と16nMになる。

    Features:Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).

  • Palbociclib (PD0332991) Isethionate

    Palbociclib (PD0332991) Isethionateは、非常に特定のCDK4CDK6の阻害剤で、 IC50 がそれぞれ11 nM と 16 nMです。

    Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.

  • Flavopiridol (Alvocidib) HCl

    Flavopiridol (Alvocidib) HClは、サイクリン依存的なkianses(CDK)を妨げるために、ATPと争いまして、 CDK1, CDK2, CDK4、CDK6 に作用すると、IC50が40 nMになり、CDK7に作用すると、IC50が 300 nMになる。

  • Dinaciclib (SCH727965)

    Dinaciclib(SCH727965)は、小説と強力なサイクリン依存的なキナーゼ阻害剤で、 CDK2、 CDK5、 CDK1、 CDK9 に作用すると、 IC50 がそれぞれ 1 nM、1 nM、 3 nM 、4 nMになる。

  • Ribociclib (LEE011)

    Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor.

  • LY2835219

    LY2835219は CDK4CDK6 の強力かつ選択的な阻害剤で、IC50 がそれぞれ 2 nM と 10 nMです。

最近チェックしたアイテム

Tags: Flavopiridol (Alvocidib)を買う | Flavopiridol (Alvocidib)供給者 | Flavopiridol (Alvocidib)を購入する | Flavopiridol (Alvocidib)費用 | Flavopiridol (Alvocidib)生産者 | オーダーFlavopiridol (Alvocidib) | Flavopiridol (Alvocidib)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description
お問い合わせ